Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

Amerikaanse aandelen Terug naar discussie overzicht

Multicell Technologies Inc (mcet)

53 Posts
Pagina: «« 1 2 3 »» | Laatste | Omlaag ↓
  2. MyOpinion 3 september 2009 16:26

    • MyOpinion

      Lid sinds: 22 jan 2005

      Laatste bezoek: 12 feb 2025

    • Aanbevelingen

      Ontvangen: 221

      Gegeven: 168

    •    Aantal posts: 1.489

    MCET heeft patent op de techniek die door pharmaceutische bedrijven in licentie gebruikt wordt om drug toxity op de lever te kunnen testen.

    MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines






    MultiCell Strengthens Its Liver Cancer Drug Target Identification and Cancer Stem Cell Research Program


    WOONSOCKET, R.I., Aug. 20 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today it has been granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines.

    The Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines were derived from normal human liver cells, and are nontumorigenic, stable in culture, and produce therapeutic plasma proteins in cell culture. The Fa2N-4 cell line has also been engineered to function as a proxy for normal human liver cells for use in performing drug toxicity assays. MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies. MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.

    MultiCell also owns exclusive worldwide rights to two issued U.S. patents (6,872,389 and 6,129,911), one U.S. patent application (U.S. 2006/0019387A1), and several corresponding issued and pending foreign patents and patent applications related to the isolation and differentiation of human liver stem cells. MultiCell previously announced it had entered into a cooperative research and development agreement with Maxim Biotech, Inc. to develop products for the study of human liver stem cells and human liver cancer.

    The role of liver stem cells in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma in humans arises by maturation arrest of liver stem cells. "MultiCell intends to use its human liver cell and liver stem cell assets to identify therapeutic targets and new drug candidates specifically targeting the treatment of primary liver cancer and intrahepatic bile duct cancer," said Jerry Newmin, Chairman & CEO of MultiCell Technologies. "We believe our engineered human liver cell lines will play an important role as proxies for normal human liver cells in our effort to identify drug targets."

    The National Cancer Institute (NCI) in 2008 stated there were approximately 21,400 new cases of hepatocellular carcinoma and intrahepatic bile duct cancer in the United States, and approximately 18,400 of those cases resulted in death. Hepatocellular carcinoma, resulting from Hepatitis B and Hepatitis C infection, is the most common cancer in some parts of the world, with more than 1 million new cases diagnosed each year. The NCI also reports that hepatocellular carcinoma is associated with cirrhosis of the liver in 50% to 80% of patients.



  6. [verwijderd] 30 juli 2010 15:13

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    MCET .0067 news:
    MultiCell Technologies Launches New Web Site
    Jul 30, 2010 7:00:00 AM
    WOONSOCKET, R.I., July 30 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has launched a new website with a fresh new look and updated information about discovery technology platforms and lead drug candidates. It also provides information to answer investors' most common questions.

    "The new website is designed to inform our shareholders, scientists and the public about the Company's proprietary therapeutic pipeline which could fill critical unmet medical needs," stated W. Gerald Newmin, Chairman and CEO of MultiCell.

    About MultiCell Technologies, Inc.
    MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools to address unmet medical needs for treatment of neurological disorders, hepatic disease and cancer.

    MultiCell's therapeutic development platform relies on patented techniques to: (i) isolate, characterize and differentiate stem cells from the human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin treatment, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

    MultiCell's drug candidates are in various stages of discovery optimization, and preclinical and clinical development:

    •MCT-125 is a Phase 2 therapeutic candidate for treatment of fatigue in MS patients, which has demonstrated efficacy in a 138-patient Phase IIa clinical trial.
    •MCT-465 is a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
    •MCT-475 is a discovery stage antibody therapeutic candidate for use in combination with dsRNA for the treatment of solid tumor cancers.
    •MCT-485 is a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.

    For more information about MultiCell Technologies, please visit www.multicelltech.com.

    Caution Regarding Forward-Looking Statements

    Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development programs. MultiCell bases these forward- looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2009, and quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

    SOURCE MultiCell Technologies, Inc.

    ----------------------------------------------
    W. Gerald Newmin
    Chairman & CEO
    MultiCell Technologies
    Inc.
    +1-401-762-0045
    MCETInvestor@MultiCelltech.com MultiCell Technologies
    Inc.
  7. Demenkovets 2 februari 2011 20:10

    • Demenkovets

      Lid sinds: 24 feb 2009

      Laatste bezoek: 08 mrt 2024

    • Aanbevelingen

      Ontvangen: 114

      Gegeven: 54

    •    Aantal posts: 9.419

    Ah er is ook gewoon een draadje van. Bij deze opgehaald.

    Koers stijgt gestaag, boekje lijkt behoorlijk dun. Zojuist de HOD op 0,0083 gezet.
  9. Demenkovets 2 februari 2011 20:17

    • Demenkovets

      Lid sinds: 24 feb 2009

      Laatste bezoek: 08 mrt 2024

    • Aanbevelingen

      Ontvangen: 114

      Gegeven: 54

    •    Aantal posts: 9.419

    zou goed kunnen, daar ligt wel ongeveer de high. was inmiddels flink gezakt weer, mogelijk een rebound weer tot over de cent.
  15. Demenkovets 2 februari 2011 20:26

    • Demenkovets

      Lid sinds: 24 feb 2009

      Laatste bezoek: 08 mrt 2024

    • Aanbevelingen

      Ontvangen: 114

      Gegeven: 54

    •    Aantal posts: 9.419

    dat is waar. misschien was dat ook wel de stimulans om me er eens enigszins in te verdiepen.

    84 bied nu, ligt nog wel wat op de 85 op de ask. daarna niks meer.
53 Posts
Pagina: «« 1 2 3 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.007
AB InBev 2 5.494
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.394
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.556
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.665
Aedifica 3 902
Aegon 3.258 322.680
AFC Ajax 538 7.087
Affimed NV 2 6.289
ageas 5.844 109.887
Agfa-Gevaert 14 2.048
Ahold 3.538 74.327
Air France - KLM 1.025 35.010
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.434
Allfunds Group 4 1.469
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.819
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 242.842
AMG 971 133.173
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 487
Antonov 22.632 153.605
Aperam 92 14.964
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.737
Arcelor Mittal 2.033 320.628
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.725
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.087
ASML 1.766 106.288
ASR Nederland 21 4.452
ATAI Life Sciences 1 7
Atenor Group 1 484
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.644
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392